<DOC>
	<DOCNO>NCT01137604</DOCNO>
	<brief_summary>An open-label phase 2 , multicenter study participant recurrent malignant glioma .</brief_summary>
	<brief_title>A Study Subjects With Recurrent Malignant Glioma</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>Inclusion Criteria 1 . Histologically confirm diagnosis Grade 3 4 malignant glioma . 2 . All subject first second recurrence follow primary management surgical resection biopsy , radiotherapy 2 prior systemic treatment addition : No prior bevacizumab treatment allow Cohort 1 Cohort 2 . Subjects must disease progression follow prior bevacizumab treatment Cohort 3 . For cohort , prior antivascular endothelial growth factor ( VEGF/VEGFR ) therapy except bevacizumab specify . 3 . Karnofsky score 70 % great . 4 . Adequately control blood pressure ( BP ) without antihypertensive medication , define BP le 150/90 mmHg screen change antihypertensive medication within 1 week prior Screening Visit . 5 . Adequate renal function , adequate bone marrow function , adequate blood coagulation function adequate liver function , define protocol . 6 . No evidence hemorrhage baseline magnetic resonance imaging ( MRI ) scan subject stable grade 1 . Exclusion criterion : 1 . Females pregnant breastfeeding . 2 . Subjects receive enzymeinducing antiepileptic agent within 14 day first dose study drug ( eg , carbamazepine , phenytoin , phenobarbital , primidone , oxcarbazepine ) . 3 . Active infection require intravenous antibiotic . 4 . Therapeutic anticoagulation warfarin , aspirin , nonsteroidal antiinflammatory drug clopidogrel ( low molecular weight heparin acceptable ) . 5 . Subjects 24hour urine protein great equal 1 gm . 6 . Prior surgical resection within 4 week , prior stereotactic biopsy within 2 week , Screening Visit . 7 . Prior radiotherapy within 12 week unless new area enhancement consistent recurrent tumor outside radiation field , biopsyproven unequivocal viable tumor histopathologic sample . 8 . Prior chemotherapy ( 6 week nitrosoureas ) , investigational agent within 4 week unless subject recover anticipated toxicity associate therapy ; prior bevacizumab therapy ( Cohorts 1 2 ) ; Cohort 3 , prior bevacizumab therapy within 3 week . 9 . Significant cardiovascular impairment : history congestive heart failure great New York Heart Association ( NYHA ) Class II ; unstable angina ; myocardial infarction stroke within 6 month first dose study drug ; cardiac arrhythmia require medical treatment . 10 . Prolongation QTc interval great 480 msec . 11 . Active hemoptysis ( bright red blood least 1/2 teaspoon ) within 3 week prior first dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>